Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-03-01
2005-03-01
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C514S841000, C552S556000, C552S595000, C552S598000, C552S602000, C552S608000
Reexamination Certificate
active
06861415
ABSTRACT:
A compound having the general formula:in which: R1is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3and —CHOHCH3; R2is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.
REFERENCES:
patent: 4386085 (1983-05-01), Teutsch et al.
patent: 4477445 (1984-10-01), Philibert et al.
patent: 4634695 (1987-01-01), Torelli et al.
patent: 4808710 (1989-02-01), de Jongh et al.
patent: 4912097 (1990-03-01), Teutsch et al.
patent: 4921845 (1990-05-01), de Jongh et al.
patent: 4943566 (1990-07-01), Nedelec et al.
patent: 4954490 (1990-09-01), Cook et al.
patent: 5064822 (1991-11-01), Philibert et al.
patent: 5073548 (1991-12-01), Cook et al.
patent: 5089488 (1992-02-01), Ottow et al.
patent: 5166199 (1992-11-01), Kasch et al.
patent: 5173483 (1992-12-01), Grandadam
patent: 5272140 (1993-12-01), Loozen
patent: 5364847 (1994-11-01), Labrie et al.
patent: 5426102 (1995-06-01), Schwede et al.
patent: 5446036 (1995-08-01), Scholz et al.
patent: 5741787 (1998-04-01), Peeters
patent: 1307784 (1992-09-01), None
patent: 057 115 (1982-08-01), None
patent: 129 499 (1984-06-01), None
patent: 136 586 (1984-09-01), None
patent: WO 8912448 (1989-12-01), None
Cook, et al.,Life Sciences, 52(2):155-162 (1993).
Cook, et al.,J. Steroid Biochem., vol. 25, Abstract 365(1986).
Heikinheimo, et al.,J. Steroid Biochem., 26(2):279-284 (1987).
Horwitz,Endocrinology, 116(6):2236-2245 (1985).
Kloosterboer, et al.,J. steroid Biochem., 31(4B):567-571 (1988).
Livingston, et al.,J. Am. Chem. Soc., 112:6449-6450 (1990).
Livingston,Adv. Med. Chem., 1:137-174 (1992).
Nieman, et al.,J. Clin. Endocrin. Metab., 61(3):536-540 (1985).
Spitznagle, et al.,Steroids, 30(4):435-438 (1977).
Teutsch, et al.,Human Reproduction, 9(1):12-31 (1994).
Acosta Carmie K.
Blye Richard P.
Cessac James W.
Kim Hyun K.
Rao Pemmaraju N.
Badio Barbara P.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
21-substituted progesterone derivatives as new... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 21-substituted progesterone derivatives as new..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 21-substituted progesterone derivatives as new... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453768